A nonhuman primate model with Alzheimer's disease-like pathology induced by hippocampal overexpression of human tau.

"Declarations Ethics approval and consent to participateAll experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Guangdong Yuan Xi Biotech Co., Ltd. (IACUC No. YXSW-2021–002) and Jinan University (IACUC No. 20210806–03) and were in full compliance with the “Guide for the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Science (est. 2006)” and “The use of nonhuman primates in research of the Institute of Laboratory Animal Science (est. 2006)” to ensure the safety of personnel and animal welfare. Consent for publicationNot applicable. Competing interestsGong Chen is a co-founder of NeuExcell Therapeutics Inc. The other authors have no conflicts of interest to declare. Competing interests Gong Chen is a co-founder of NeuExcell Therapeutics Inc. The other authors have no conflicts of interest to declare."

"Funding This work is supported by the National Natural Science Foundation of China (Grant No. 31970906), the Guangdong Provincial Natural Science Foundation (Grant No. 2020A1515010083), the Guangdong Grant ‘Key Technologies for Treatment of Brain Disorders’ (Grant No. 2018B030332001), the Guangzhou Grant ‘Direct Astrocyte-to-Neuron Conversion to Treat Brain Disorders in NHPs’ (Grant No. 202206060002), the Pearl River Innovation and Entrepreneurship Team (Grant No. 2021ZT09Y552) and Yi-Liang Liu Endowment Fund from Jinan University Education Development Foundation."